Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours

BACKGROUND: TAS-102 consists of α, α, α-trifluorothymidine (TFT) and an inhibitor of thymidine phosphorylase (TPI). We conducted a dose-escalation phase I study in Japanese patients with advanced solid tumours. METHODS: TAS-102 was administered twice daily on days 1–5 and days 8–12 in a 28-day cycle...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Doi, T, Ohtsu, A, Yoshino, T, Boku, N, Onozawa, Y, Fukutomi, A, Hironaka, S, Koizumi, W, Sasaki, T
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2012
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3405214/
https://ncbi.nlm.nih.gov/pubmed/22735906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.274
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars